May 28, 2021 / 12:30PM GMT
Operator
Good day, everyone, and welcome to Myovant Sciences MYFEMBREE FDA approval conference call. Today's call is being recorded.
At this time, I would like to turn the call over to Ryan Crowe, Vice President of Investor Relations at Myovant. Please go ahead.
Ryan Crowe - Myovant Sciences Ltd. - VP of IR
Thank you, operator. Good morning, and thank you for joining us today to discuss the FDA approval of MYFEMBREE for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Our press release as well as the slides that will be presented today are available on our Investor Relations website, investors.myovant.com.
Joining me for today's call are Dave Marek, Myovant's Chief Executive Officer; Frank Karbe, President and Chief Financial Officer; Lauren Merendino, Chief Commercial Officer; and Dr. Juan Camilo Arjona, Chief Medical Officer.
During the course of this conference call, we'll be making forward-looking statements. These include plans and expectations with respect to our products, product
Myovant Sciences Ltd and Pfizer Inc Receive FDA Approval for MYFEMBREE® Transcript
May 28, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers